The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells
Open accessAbstract
SUMMARY We report a Jak2V617F knock-in mouse myeloproliferative neoplasm (MPN) model resembling human polycythemia vera (PV). The MPN is serially transplantable and we demonstrate that the hematopoietic stem cell (HSC) compartment has the unique capacity for disease initiation but does not have a significant selective competitive advantage over wild type HSCs. In contrast, myeloid progenitor populations are expanded and skewed towards the erythroid lineage, but cannot transplant the disease. Treatment with a JAK2 kinase inhibitor ameliorated the MPN phenotype, but did not eliminate the disease-initiating population. These findings provide insights into the consequences of JAK2 activation on HSC differentiation and function and have the potential to inform therapeutic approaches to JAK2V617F positive MPN. SIGNIFICANCE The JAK2V617F mutation is a promising candidate for molecularly targeted therapy in MPN. Early data from JAK2 inhibitor clinical trials have called into question the capacity of these compounds to alter the natural history of JAK2V617F mediated MPN. Determining the effect of JAK2 inhibitors on the disease-initiating population requires a model in which the JAK2V617F allele is expressed at physiological levels in hematopoietic stem and progenitor cells, as it is in humans. Our model demonstrates that JAK2V617F causes expansion of erythroid progenitors but that only the HSC compartment can initiate disease in a transplanted mouse. We further demonstrate that the HSC compartment, the definitive target for curative therapy of JAK2V617F mediated MPN, is resistant to treatment with a JAK2 inhibitor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Self-citationConversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836 · cited 1×
“Little is known about the function of TET2, but it was recently shown that TET1 has an enzymatic function in epigenetic regulation (Tahiliani et al., 2009).”
BackgroundAcquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Le Couédic, J.-P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,544
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
Kiel, M. J., Yilmaz, Ö. H., Iwashita, T., Yilmaz, O. H., Terhorst, C., & Morrison, S. J. (2005) · Cell · doi:10.1016/j.cell.2005.05.026 · Cited by 3,168
Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
Self-citationPurification and Characterization of Mouse Hematopoietic Stem Cells
Spangrude, G. J., Heimfeld, S., & Weissman, I. L. (1988) · Science · doi:10.1126/science.2898810 · Cited by 2,824
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776 · cited 8×
“Little is known about the function of TET2, but it was recently shown that TET1 has an enzymatic function in epigenetic regulation (Tahiliani et al., 2009).”
BackgroundInfluentialTransformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9
Krivtsov, A. V., Twomey, D., Feng, Z., Stubbs, M. C., Wang, Y., Faber, J., Levine, J. E., Wang, J., Hahn, W. C., Gilliland, D. G., et al. (2006) · Nature · doi:10.1038/nature04980 · Cited by 1,513 · cited 4×
“…profiling of Jak2+/VF LSKs demonstrated a robust enrichment of myeloid progenitor differentiation signatures including those derived from MEP (Krivtsov et al., 2006) and Pre-CFU-E cells (Pronk et al., 2007), respectively, indicating that Jak2V617F instructs HSC differentiation, consistent…”
BackgroundInfluentialSelf-citation
Cited by
JAKs and STATs in immunity, immunodeficiency, and cancer
O'Shea, J. J., Holland, S. M., & Staudt, L. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1202117 · Cited by 927
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
Vainchenker, W., & Kralovics, R. (2017) · Blood · doi:10.1182/blood-2016-10-695940 · Cited by 616
Exome-wide association study of plasma lipids in >300,000 individuals
Charge Diabetes Working Group, Liu, D. J., The EPIC-InterAct Consortium, EPIC-CVD Consortium, GOLD Consortium, Program, V. M. V., Peloso, G. M., Yu, H., Butterworth, A. S., Wang, X., et al. (2017) · Nature Genetics · doi:10.1038/ng.3977 · Cited by 540
JAK/STAT signaling in hematological malignancies
Vainchenker, W., & Constantinescu, S. N. (2013) · Oncogene · doi:10.1038/onc.2012.347 · Cited by 528
Wolach, O., Sellar, R. S., Martinod, K., Cherpokova, D., McConkey, M., Chappell, R. J., Silver, A. J., Adams, D., Castellano, C. A., Schneider, R. K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan8292 · Cited by 481
Self-citationThe AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis
Fidler, T. P., Xue, C., Yalcinkaya, M., Hardaway, B., Abramowicz, S., Xiao, T., Liu, W., Thomas, D. G., Hajebrahimi, M. A., Pircher, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03341-5 · Cited by 474
Self-citationSafety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
Pardanani, A., Gotlib, J. R., Jamieson, C., Cortes, J. E., Talpaz, M., Stone, R. M., Silverman, M. H., Gilliland, D. G., Shorr, J., & Tefferi, A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.8021 · Cited by 400
Self-citationNew mutations and pathogenesis of myeloproliferative neoplasms
Vainchenker, W., Delhommeau, F., Constantinescu, S. N., & Bernard, O. A. (2011) · Blood · doi:10.1182/blood-2011-02-292102 · Cited by 395
Kleppe, M., Kwak, M., Koppikar, P., Riester, M., Keller, M., Bastian, L., Hricik, T., Bhagwat, N., McKenney, A. S., Papalexi, E., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0736 · Cited by 315
TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms
Fleischman, A. G., Aichberger, K. J., Luty, S. B., Bumm, T. G., Petersen, C. L., Doratotaj, S., Vasudevan, K. B., LaTocha, D. H., Yang, F., Press, R. D., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348144 · Cited by 292
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond
Quintás-Cardama, A., Kantarjian, H., Cortes, J., & Verstovsek, S. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3264 · Cited by 290
Caiado, F., Pietras, E. M., & Manz, M. G. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201541 · Cited by 289
“JAK2V617F reduces the self-renewal capacity of individual HSCs but leads to expansion of downstream progenitor cells (Mullally et al., 2010; Kent et al., 2013).”
BackgroundMolecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance
Quintás-Cardama, A., & Verstovsek, S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0284 · Cited by 284
Kleppe, M., Koche, R., Zou, L., van Galen, P., Hill, C. E., Dong, L., De Groote, S., Papalexi, E., Hanasoge Somasundara, A. V., Cordner, K., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.11.009 · Cited by 279
Liu, F., Zhao, X., Perna, F., Wang, L., Koppikar, P., Abdel-Wahab, O., Harr, M. W., Levine, R. L., Xu, H., Tefferi, A., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.020 · Cited by 273
Macrophage Inflammation, Erythrophagocytosis, and Accelerated Atherosclerosis in Jak2 V617F Mice
Wang, W., Liu, W., Fidler, T., Wang, Y., Tang, Y., Woods, B., Welch, C., Cai, B., Silvestre-Roig, C., Ai, D., et al. (2018) · Circulation Research · doi:10.1161/circresaha.118.313283 · Cited by 262
Macrophages support pathological erythropoiesis in polycythemia vera and β-thalassemia
Ramos, P., Casu, C., Gardenghi, S., Breda, L., Crielaard, B. J., Guy, E., Marongiu, M. F., Gupta, R., Levine, R. L., Abdel-Wahab, O., et al. (2013) · Nature Medicine · doi:10.1038/nm.3126 · Cited by 227
“We utilized mice carrying a Jak2-V617F conditional knock-in 40 crossed with animals expressing cre-recombinase under the control of the hematopoietic vav regulatory elements 56 (VAV-Cre) to generate animals affected by Polycythemia vera.”
BackgroundMethodInfluentialSelf-citationVan Egeren, D., Escabi, J., Nguyen, M., Liu, S., Reilly, C. R., Patel, S., Kamaz, B., Kalyva, M., DeAngelo, D. J., Galinsky, I., et al. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.02.001 · Cited by 206
Self-citationJAK2V617F-Mediated Clonal Hematopoiesis Accelerates Pathological Remodeling in Murine Heart Failure
Sano, S., Wang, Y., Yura, Y., Sano, M., Oshima, K., Yang, Y., Katanasaka, Y., Min, K.-D., Matsuura, S., Ravid, K., et al. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.05.013 · Cited by 170
Myeloproliferative neoplasm stem cells
Mead, A. J., & Mullally, A. (2017) · Blood · doi:10.1182/blood-2016-10-696005 · Cited by 169
Self-citationFuster, J. J., & Walsh, K. (2018) · Circulation Research · doi:10.1161/circresaha.117.312115 · Cited by 162
Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera
Casu, C., Oikonomidou, P. R., Chen, H., Nandi, V., Ginzburg, Y., Prasad, P., Fleming, R. E., Shah, Y. M., Valore, E. V., Nemeth, E., et al. (2016) · Blood · doi:10.1182/blood-2015-10-676742 · Cited by 148
JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation
Edelmann, B., Gupta, N., Schnoeder, T. M., Oelschlegel, A. M., Shahzad, K., Goldschmidt, J., Philipsen, L., Weinert, S., Ghosh, A., Saalfeld, F. C., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci90312 · Cited by 138
Janus kinase deregulation in leukemia and lymphoma
Chen, E., Staudt, L. M., & Green, A. R. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.017 · Cited by 123
“…levels within hematopoiesis, JAK2-V617F gene-targeted mice display expansion of lineage-restricted myeloid compartments, increased numbers of BFU-E, CFU-GM, and CFU-Megs, together with increased erythroid and megakaryocytic terminal differentiation (Li et al., 2010b; Mullally et al., 2010).”
InfluentialJacquelin, S., Straube, J., Cooper, L., Vu, T., Song, A., Bywater, M., Baxter, E., Heidecker, M., Wackrow, B., Porter, A., et al. (2018) · Blood · doi:10.1182/blood-2018-04-846220 · Cited by 99
Self-citationAKT is a therapeutic target in myeloproliferative neoplasms
Khan, I., Huang, Z., Wen, Q., Stankiewicz, M. J., Gilles, L., Goldenson, B., Schultz, R., Diebold, L., Gurbuxani, S., Finke, C. M., et al. (2013) · Leukemia · doi:10.1038/leu.2013.167 · Cited by 74
Austin, R. J., Straube, J., Bruedigam, C., Pali, G., Jacquelin, S., Vu, T., Green, J., Gräsel, J., Lansink, L., Cooper, L., et al. (2020) · Leukemia · doi:10.1038/s41375-019-0638-y · Cited by 61
Self-citationGrabek, J., Straube, J., Bywater, M., & Lane, S. W. (2020) · Cells · doi:10.3390/cells9081901 · Cited by 53
Self-citationLoss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera
Tsuruta-Kishino, T., Koya, J., Kataoka, K., Narukawa, K., Sumitomo, Y., Kobayashi, H., Sato, T., & Kurokawa, M. (2017) · Oncogene · doi:10.1038/onc.2016.478 · Cited by 41
Shepherd, M. S., Li, J., Wilson, N. K., Oedekoven, C. A., Li, J., Belmonte, M., Fink, J., Prick, J. C. M., Pask, D. C., Hamilton, T. L., et al. (2018) · Blood · doi:10.1182/blood-2017-12-821066 · Cited by 33
Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN
Schnöder, T. M., Eberhardt, J., Koehler, M., Bierhoff, H. B., Weinert, S., Pandey, A. D., Nimmagadda, S. C., Wolleschak, D., Jöhrens, K., Fischer, T., et al. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2354-1 · Cited by 13
Metadata
- Authors
- Mullally, A., Lane, S. W., Ball, B., Megerdichian, C., Okabe, R., Al-Shahrour, F., Paktinat, M., Haydu, J. E., Housman, E., Lord, A. M., Wernig, G., Kharas, M. G., Mercher, T., Kutok, J. L., Gilliland, D. G., & Ebert, B. L.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2010-06
- Volume
- 17
- Issue
- 6
- Pages
- 584-596
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2029318743
- Cited by
- 395
- References
- 59
- FWCI
- 11.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.